BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies

Summary

This study is an exploratory research on single arm, open, and improved "3+3" dose escalation. BGT007 will explore two dose groups, namely (Group A: 3.0X10 \^ 8 3 cases, Group B: 6.0X10 \^ 8 3 cases), and receive the same dose infusion after observing lower adverse reactions and initial benefits (SD or PR), with an interval of one month. Each subject can receive a maximum of 3 infusions in total.

Timeline

Start

2024-11-30

Primary completion

2026-08-31

Completion

2027-08-31

Drugs

Indications